Navigation Links
Diabetes Drug Avandia Could Weaken Bones
Date:12/2/2007

Mouse study suggests it boosts production of bone-eroding cells

MONDAY, Dec. 3 (HealthDay News) -- Avandia, a drug used by millions of diabetes patients, may contribute to bone loss, according to a new study conducted in mice.

Experts fear that, over the long term, Avandia (rosiglitazone) may speed osteoporosis, the thinning of the bones that can lead to dangerous and even fatal fractures.

The findings appear in the Dec. 2 online issue of Nature Medicine.

"Our study suggests that long-term rosiglitazone usage in the treatment of type II diabetes may cause osteoporosis due to both increased bone resorption and decreased bone formation," said study senior author Ron Evans, a professor at the Salk Institute for Biological Studies in La Jolla, Calif. "Because Avandia is effective in controlling glucose and restoring the body's sensitivity to insulin, we do not recommend that people stop their treatment. You must balance the benefits against the complications."

"Anyone who is already at risk for osteoporotic fractures should consider an alternative anti-diabetic drug," added Paul Brandt, an associate professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine, in College Station. "There are many alternatives, " he said.

"It may [also] be possible to blunt some of Avandia's effects with anti-osteoporosis drugs such as bisphosphonates, raloxifene, vitamin D and calcium," Brandt added.

Earlier this year, Avandia and four other diabetes drugs from the same class were given a "black box" warning by the U.S. Food and Drug Administration. That warning advises users of an increased risk of heart failure while on the drug.

The black box message is the FDA's strongest label warning.

With an estimated 3.5 million or more U.S. patients taking Avandia, the public health impact from the point of view of both heart failure and bone degradation could be substantial, experts say.

Avandia affects a key cellular protein called the peroxisome proliferator-activated receptor (PPAR-gamma). In their study, the California team discovered that, in mice, activating this receptor also stimulates the production of osteoclasts, cells whose key function is to degrade bone.

Proper bone health is maintained by a balance between osteoclasts and osteoblasts, the cells that build bone up.

If either side is out of whack, so to speak, bones become thinner, more fragile and prone to fracture.

The current results are particularly disturbing in light of prior studies, the experts said.

"It was previously known that Avandia mediates bone loss by inhibiting bone formation," Evans explained. "Our work identified an additional mechanism, in which Avandia promotes bone resorption. These are the two parts of the checks-and-balance system that maintains bone in good shape. The drug weakens both sides of the balance mechanism, leading to an increased risk for osteoporosis."

"Previous research showed that Avandia reduced osteoblasts," Brandt added. "Combine the two, and you're going to get thinning of the bone."

More information

For more on diabetes drugs, visit the U.S. Food and Drug Administration.



SOURCES: Ron Evans, Ph.D., professor, The Salk Institute for Biological Studies, and investigator, Howard Hughes Medical Institute, March of Dimes Chairman, Molecular and Developmental Biology, La Jolla, Calif.; Paul Brandt, Ph.D., associate professor, neuroscience and experimental therapeutics, Texas A&M Health Science Center College of Medicine, College Station; Dec. 2, 2007, Nature Medicine online


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Adverse housing conditions contribute to diabetes risk
2. RAND finds cases of undiagnosed diabetes drop sharply
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Discovery of sugar sensor in intestine could benefit diabetes
6. Despite overeating, morbidly obese mice gain protection against diabetes
7. Heart Attack Boosts Diabetes Risk
8. Obesity Doesnt Always Equal Diabetes
9. Sugary Sodas High in Diabetes-Linked Compound
10. Treating diabetes during pregnancy can break link to childhood obesity
11. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Diabetes Drug Avandia Could Weaken Bones
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: